Frontier Medicines

Frontier Medicines, founded in 2018 and based in South San Francisco, is a private, pre-revenue biotech focused on covalent drug discovery. Its core asset is The Frontier™ Platform, which integrates chemoproteomics and artificial intelligence to create a 'Druggability Atlas' of novel binding sites across over 90% of the human proteome. This platform enables the company to build a pipeline of precision medicines against difficult-to-drug targets in oncology and immunology, supported by a significant strategic collaboration with AbbVie. Frontier's mission is to deliver breakthrough treatments by targeting previously inaccessible disease drivers.

The Frontier™ Platform integrates chemoproteomics and AI to map novel, ligandable binding sites across the human proteome, creating a 'Druggability Atlas' to enable the discovery of covalent small-molecule drugs against previously undruggable targets.

Frontier operates in the competitive field of next-generation small-molecule drug discovery, competing with other chemoproteomics-focused biotechs (e.g., Revolution Medicines, Relay Therapeutics) and companies specializing in covalent chemistry and targeted protein degradation. Its differentiation lies in the scale of its proteome-wide mapping and the integration of AI to accelerate discovery.